The identification of potential biomarkers to monitor disease progression and treatment efficacy is necessary for RA patients’ management, while there are no relevant studies reporting the correlation of CDC42 with treatment efficacy in RA patients. The gene discussed is CDC42; the disease is rheumatoid arthritis.